Bio-Rad Laboratories, Inc. BIO
Set alert
366.16 USD -6.02 -1.62%
At close
367.99 +1.83 +0.50%
Pre-market · Nov 3, 5:54 AM ET
361.27 Day range 377.90
236.73 52-week range 396.23
- YTD
- +20.85%
- 1 year
- +14.59%
- Open
- 374.79
- Prev close
- 372.18
- Mkt cap
- 9.80B
- Vol
- 211.83K
- Avg vol
- 254.03K
- EPS
- 7.89
- P/E
- 46.41
- Div yield
- 0.00%
More statistics
- Low
- 361.27
- High
- 377.90
- Forward P/E
- 37.57
- Beta
- 1.06
- Short ratio
- 4.17
- Inst. own
- 91.74%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 374.80
- 200-d avg
- 313.41
- 1y target
- 335.00
6M chart
Events in this range
- Aug 4, 2026Earnings: 2.62; estimate 1.75; surprise 49.71%
- Aug 5, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Aug 5, 2026Rating: RBC Capital · Outperform → Outperform
- Aug 5, 2026Rating: Citigroup · Neutral → Neutral
- Aug 7, 2026Rating: RBC Capital · Outperform → Outperform
Signals (25)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 5, 2026 | 2 months ago |
| RSI: Overbought | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Jul 28, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 10, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 23, 2026 | 4 months ago |
| SMA: Bearish | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 9, 2026 | 4 months ago |
Newest 20 of 25.
Analyst view
Consensus: hold
Hold
Price target (mean) 335.00 -8.5% downside
Now 366.16
- Target (low)
- 280.00
- Target (mean)
- 335.00
- Target (high)
- 390.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.23 | 2.16 – 2.29 | 2.26 | -1.6% | 649.95M | -0.5% | 2 |
| Next quarter | 3.02 | 2.74 – 3.30 | 2.51 | +20.3% | 695.40M | +0.3% | 2 |
| Current year | 9.45 | 8.85 – 10.10 | 9.92 | -4.7% | 2.57B | -0.5% | 3 |
| Next year | 9.75 | 8.75 – 10.90 | 9.45 | +3.1% | 2.62B | +2.1% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 5, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Aug 5, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 5, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| May 1, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Apr 7, 2026 | Citigroup | Downgrade | Buy | Neutral |
| Feb 16, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Oct 30, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 30, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 1, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 1, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jun 9, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| May 2, 2025 | UBS | Maintained | Buy | Buy |
| May 2, 2025 | Citigroup | Maintained | Buy | Buy |
| May 2, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 17, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Feb 12, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jan 14, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| Dec 9, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 31, 2024 | Citigroup | Maintained | Buy | Buy |
| Oct 31, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 1, 2024 | Citigroup | Upgrade | Neutral | Buy |
| Aug 27, 2024 | Wells Fargo | Initiated | — | Equal-Weight |
| Aug 16, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 2, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 2, 2024 | Citigroup | Maintained | Neutral | Neutral |
| May 8, 2024 | UBS | Maintained | Buy | Buy |
| Apr 3, 2024 | Citigroup | Downgrade | Buy | Neutral |
| Feb 16, 2024 | UBS | Maintained | Buy | Buy |
| Feb 16, 2024 | RBC Capital | Maintained | Outperform | Outperform |